

May 2022



ON eNews



Welcome to our May 2022 eNews

Now where did you put those business cards?

It's my pleasure to welcome you to this month's One Nucleus eNews, our regular opportunity to share with you some of the highlights of what our members have been up to, upcoming opportunities and more.

It feels like the weather is on the up and so is the momentum and dealmaking in the sector, not least as international travel continues to open and conference and partnering meeting attendance

gradually returns to face-to-face.

The frequent social media postings showing a picture of an airport and containing words along the lines of '... first time in 2 years' an illustration of how such momentum is building.

That said, whilst experiencing the in-person buzz of attending BioTrinity last week, where there was clearly a 'glad to be out' energy on arrival, I, like many other, also took advantage of the virtual world with partnering meetings online. So, it's not entirely clear as yet that we all just revert to our pre-2020 routines, perhaps rightly so.



Picture from [OBN](#)



Partnering Beyond Borders

Where I wrote in the last issue of the feeling of reconnecting with people, as we saw in-person events with our members increasing in frequency, this month has a true growing on feeling as we welcome numerous international guests and plan ahead for the autumn.

As you receive this e-newsletter today, we will be gathering with a delegation from Denmark here in Cambridge and Stevenage, kindly hosted by Mills & Reeve and Stevenage Bioscience Catalyst, respectively. This a curtain raiser for our attending this week's AngloNordic Conference in London tomorrow.

MILLS & REEVE

Achieve more. Together.



STEVENAGE BIOSCIENCE
CATALYST

Following hot on the heels will be delegations visiting from Belgium, Finland and Switzerland in the coming weeks. Great opportunities all of them to connect directly with potential partners and also to gain first-hand insight into the dynamics in these different regions as you evaluate your forward planning.

A key goal of One Nucleus is to bring the information, insight and opportunity awareness to our events and online communications that enables our members to be as well prepared and connected as possible when investing in their corporate and product development activities since we absolutely accept the need for our members to succeed internationally as well as at home.

Proud to be seen with our Members @ Bio-Europe



With the above requirement for international partnering in mind, it is great to be continuing our collaboration with EBD Group, who remain firmly committed to supporting One Nucleus in creating the best possible platforms for our members to engage in dealmaking. I have always felt there is real complementarity between first rate regionally focussed, not-for-profit membership groups such


as One Nucleus and the large global partnering commercial conference providers such as EBD Group. It is both pleasing and reassuring therefore to be collaborating with a like-minded firm on the other side of that equation. To highlight one of the benefits of the collaboration, set out below is the offer of support we are able to offer our members keen to be seen at

[BioEurope 2022, Leipzig 24-26 October:](#)

- Discounted delegate rates to register
- Company logo circulating on the on-stand screen
- Inclusion in the soft copy One Nucleus at BioEurope 2022 brochure
- Business cards displayed on the stand
- Social media and newsletter promotion around the event
- Opportunity to be part of a promotional video
- One Nucleus will of course staff the booth and field any enquiries

No time to waste in requesting your delegate rate discount code for use at the time of booking or to secure your space to raise profile on the One Nucleus booth. For further information please email the team at info@onenucleus.com at your convenience.

Aiming to be at our best



Much like great sports teams - along with taking advantage of the engagement mechanisms such as the above - maximising performance also relies on your company and individuals doing the right things to be the best and most effective version of yourself that you can be. This is where numerous other aspects of the One Nucleus membership proposition adds further value. Examples include

our continuing webinars in the Life Science Marketing Group and Employer of Choice series. Recent examples were with our friends at Sookio regarding '[The Power of LinkedIn](#)' and



Singular Talent discussing '[Biotech Talent Trends 2022](#)', respectively. Across the One Nucleus [website](#) you will find the full range of opportunities to learn, be seen, save on lab supplies and other third-party services and more via engaging with us. Our driver is to see our members and wider network succeed, given that it leads to all the benefits such as improved patient outcomes, job

creation, sustainable development and wealth creation – benefits we will all reap as citizens and patients.

There is such a consistent and high volume of great news from our members and network that we couldn't hope to capture it all in one newsletter obviously. Reading further, you will see a selection of upcoming opportunities, member news and engagement highlights such as ON Helix, Networking Mixers, BioWednesdays, Training Courses and more.

You are able to keep up to date with the news from our members and our team via our [website](#), [LinkedIn](#) or [Twitter](#) pages. If you are seeking to join one of the teams heading for success, the application deadline for the One Nucleus vacancy for a Business Development Manager looms at 10 May 2022 and many other roles are posted to the [One Nucleus Jobs page](#) and our [One Nucleus Members' Jobs group](#) on LinkedIn

The One Nucleus team remain available to respond to any questions you may have and look forward to supporting you wherever possible.

Tony Jones

CEO, One Nucleus

ON Helix - AI Discovered Drugs in Action

Our one-day conference addressing key bio innovation trends, from developments in life science and technology research to their translation into new diagnostics, prevention tools and treatments is back at the Babraham Research Campus on 7 July.

A bio innovation trend that can't be ignored is the use of Artificial Intelligence algorithms to enhance drug discovery efficacy. With the rise in the availability of omics data, the potential of new targets labelled 'undruggable' to become 'druggable' and the many chemistry databases developed in recent years, applied AI to help research for better targets and matching compounds made a lot of sense on paper. In reality however, a very diverse quality of technologies developed, with a question remaining on adoption within existing drug discovery processes.

As we are now seeing the approval of the first AI discovered drugs, the ON Helix panel discussion Bio Innovation in Therapeutics – AI Discovered Drugs in Action will gather companies providing AI tools for innovative approaches to drug discovery from Pharmenable and Ladder Therapeutics, to larger players integrating AI tools into existing processes. These include Charles River (having experience of collaboration with Valo Health) and Sanofi (with its high profile large deals with Excientia and Owking).

ON Helix offers much more, so do check the [website](#) for updates. There will be limited in-person capacity, therefore we highly recommend [registering early](#) to ensure you reserve your place and reconnect with the network on 7 July.

A promotional banner for the ON Helix event. The background features a stylized molecular structure with pink and purple spheres. A white rounded rectangle in the center contains the event details: "7 July 2022 | Cambridge & 4, 5, 6 July 2022 Digital" and the "on helix" logo, where the 'o' is a DNA double helix. In the bottom left corner is the "one nucleus" logo, and in the bottom right is a dark blue button with the text "Register here".

7 July 2022 | Cambridge &
4, 5, 6 July 2022 Digital

on helix


one nucleus

Register here



Where to Join our Cambridge Networking Mixers

Free to attend and open to all, our Networking Mixers are a great way to connect with the local life science ecosystem - here's a handy map of our next Cambridge based mixers, we look forward to seeing you!



Creating a Scientific Superpower

QElI Conference Centre
20 June 2022

How do we fully unlock the country's innovation potential to catapult global Britain?

REGISTER NOW

IEG **BIDWELLS**



Continuing in the vein of supporting life science companies on their growing journey, the Virtual Innovation Centre has two exciting events this month covering the investor decision process and the key elements to consider when contracting.

[Exploring the Investor Decision Process - 17 May 2022 11.00 – 12.00 hrs - Online](#)

This webinar will review the key points investors consider when reviewing investment opportunities including business models, business plans, company valuation, operations and the funding negotiations.

It will cover:

- key considerations for investors when evaluating a potential equity investment
- comparisons of the most common types of equity finance available
- de-mystifying some of the key terms that commonly arise in relation to such types of funding
- highlighting some of the areas where red flags are often encountered during due diligence in fundraising transactions
- discussion of the dynamics between a lead investor and follow-on investors

[Contracting in Confidence - 24 May 2022 – 08.30 – 10.00 hrs - In-person](#)

With the increasing amount of technology needed to discover and develop drugs, contracting is now a key part of R&D companies' activities. It is usually a very good way to access the best expertise on specific domains whilst managing resources efficiently but comes with some key considerations around confidentiality and research outcomes. Finding the right partner as well as having the right legal framework in place becomes essential and this workshop will review the key elements to consider when recruiting a CRO as well as the most efficient way to 'contract in confidence'.

Please contact Aline, aline@onenucleus.com if you would like to discuss the **VIC** or the **ON Helix 'Innovation Engine Room'**.

Virtual Innovation Centre Workshop



Upcoming Events and Training Courses

One Nucleus Events

5 May | Networking for Biologics Innovators - [register](#)

10 May | Connect with Belgian Life Science- [register](#)

11 May | Employer of Choice Webinar: Creating a Destination Workplace - [register](#)

12 May | Networking Mixer - [register](#)

12 May | Collaboration Opportunities with Ono Pharmaceutical in Non-clinical Stage or Late Stage of Drug Discovery Programs - [register](#)

17 May | VIC Workshop – Exploring the Investor Decision Process - [register](#)

18 May | UK – Finland Life Science Networking lunch - [register](#)

24 May | VIC Workshop – Contracting in Confidence - [register](#)

24 May | How and When to Prepare for the Arrival of the Unitary Patent - [register](#)

26 May | Networking Mixer - [register](#)

6 July | One Nucleus Summer Life Sciences Dinner - [register](#)

7 July In Person | 4 - 6 July Digital | ON Helix - [register](#)

One Nucleus Training Courses

25 May | Online Performance Evaluation & Post-Market Surveillance on Medical Devices & IVD's Under MDR & IVDR - [register](#)

8 June | Online Introduction to Drug Discovery: From Idea to Clinical Candidate (two day course) - [register](#)

14 June | Introduction to Contracts - [register](#)

Industry Events

4-5 May | **Member Discount:** Anglonordic Life Science Conference 2022 - [find out more](#)

8-10 May | Target to Patient - Creating tomorrow's drug discovery toolbox - [find out more](#)

9-13 May | BioNJ's 12th Annual BioPartnering Virtual Conference - [find out more](#)

17 May | **Complimentary Registration for Members:** Bio Integrates - [find out more](#)

18-19 May | **Member Discount:** Knowledge for Growth 2022 - [find out more](#)

18 May | Genomics England Research Summit 2022 - [find out more](#)

25 May | 2022 Bionow Pharma Manufacturing Conference - [find out more](#)

31 May | Formulating the Future: Accelerating Oral Drug Development & Manufacturing - [find out more](#)

31 May | BiotechBikers Networking Ride - [find out more](#)

13-16 June | **Member Discount:** BIO International Convention - [find out more](#)

20 June | PING Conference 2022 – The Golden Age for Life Sciences Innovation - [find out more](#)

20 June | Creating a Scientific Superpower - [find out more](#)

Corporate Patron

AstraZeneca 

Corporate Sponsors

CHARLES STANLEY
Wealth Managers

CHESTERFORD
RESEARCH PARK
CAMBRIDGE

FISH
FISH & RICHARDSON

 **MSD**
INVENTING FOR LIFE

TaylorWessing

ThermoFisher
SCIENTIFIC

New! ProductLife Group Training Course

An exciting new collaboration between One Nucleus and ProductLife Group, this two-day online course is an opportunity for those knowledgeable in Medical Device industry areas such as Research & Development, Regulatory Affairs and Quality Management to extend their current knowledge into Performance Evaluation Requirements for MDs/IVDs under MDR/IVDR and Post Market Surveillance and Post Market Clinical Follow Up requirements for MDs/IVDs under MDR/IVDR.

The course will be led by experts within PLG who's company mission is to improve human health by delivering regulatory compliance services for the safe and effective use of medical solutions.

The first delivery of the course is 25-26 May 2022. Places are limited so sign up now to secure your place.

For further details and how to register visit the One Nucleus website: '[Performance Evaluation & Post-Market Surveillance on Medical Devices & IVDs under MDR & IVDR](#)'

Online Training Course: Performance Evaluation & Post-Market Surveillance on Medical Devices & IVDs under MDR & IVDR

25-26 May 2022

one
nucleus



31ST MAY 2022, 5-9PM


MELBOURN SCIENCE PARK,
CAMBRIDGE RD, MELBOURN, ROYSTON, UK

Networking, two ride distances and pre-
and post-ride refreshments

#MaketheConnection

MORE INFO & SIGN UP DETAILS AT:
BIOTECHBIKERS.COM

In partnership with



Member Update



If the excitement around microbiome research is shared across the biotech and pharma industry it is because of its vast potential in a broad range of indications from infectious diseases to immune-oncology or CNS.

The reason for this high potential is the richness of data that can be extracted, analyzed, interpreted from individuals as well as populations that raises questions around the Commercial Opportunities from Microbiome Research. Fish & Richardson partner Chad Shear discussed the question of IP, regulatory considerations and value propositions with a panel of microbiome experts that you can [watch now on our YouTube channel](#).

Deal of the Month

Cambridge Innovation Capital Raises £225 million Fund II

The oversubscribed Fund II is giving CIC a fund in excess of £500 million to manage. Created 9 years ago, originally to fund innovative companies from the Cambridge area it is now reaching a scale to support companies along their life cycle with capital, strategic and operational support.

In addition to an impressive portfolio of mature deeptech and life sciences companies including the likes of CMR Surgical, Bicycle Therapeutics, Inivata or Microbiotica, CIC is a strong supporter of early-stage innovators being the co-founder of two Cambridge-based business accelerators, DeepTech Labs and Start Codon.

A fantastic additional piece to the jigsaw support to innovation in life sciences in the region. [Read the full press release here](#).

Funding & Support

The annual [accelerate@babraham](#) start-up competition is now open for applications until 7 June.

The programme will offer five entrepreneurs the opportunity to dedicate five months to the exploration and development of their science in the company of an exceptional network of strategic partners and supporters, located on Babraham Research Campus.

Successful candidates will get five months of lab space and a £10,000 cash prize.

See more information on the programme and application on [Accelerate@babraham](#) website.